These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 32179081)
21. Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report. Yun JS; Scardamaglia L; Tan CG; McCormack CJ Australas J Dermatol; 2022 May; 63(2):e155-e158. PubMed ID: 35138643 [TBL] [Abstract][Full Text] [Related]
22. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid. Yang J; Gao H; Zhang Z; Tang C; Chen Z; Wang L; Yang F; Chen S; He S; Liu S; Tang L; Xu Y; Hu Y; Ma L; Zhao Y; Luo X Dermatol Ther; 2022 Aug; 35(8):e15648. PubMed ID: 35715972 [TBL] [Abstract][Full Text] [Related]
23. Severe pemphigoid nodularis successfully treated with dupilumab. Jendoubi F; Bost C; Tournier E; Paul C; Konstantinou MP Dermatol Ther; 2022 Sep; 35(9):e15727. PubMed ID: 35861645 [No Abstract] [Full Text] [Related]
24. Successful treatment of eczema-like bullous pemphigoid and typical bullous pemphigoid with dupilumab: two case reports. Xu Y; Song W; Cai Y; Huang R; Wei J; Liu H; Peng X; Zeng K; Li C Int J Dermatol; 2023 Mar; 62(3):e144-e146. PubMed ID: 36214412 [No Abstract] [Full Text] [Related]
25. Reply to: 'Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab' by Baffa et al. Sun L; Brazão C; Mancha D; Soares-de-Almeida L; Filipe P J Eur Acad Dermatol Venereol; 2023 May; 37(5):e578-e580. PubMed ID: 36681888 [No Abstract] [Full Text] [Related]
26. Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study. Velin M; Dugourd PM; Sanchez A; Bahadoran P; Montaudié H; Passeron T J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e539-e542. PubMed ID: 35143077 [No Abstract] [Full Text] [Related]
27. A successful case of vesicular pemphigoid concurrent with pulmonary tuberculosis with dupilumab. Shan Y; Zuo YG Dermatol Ther; 2022 Apr; 35(4):e15330. PubMed ID: 35080079 [No Abstract] [Full Text] [Related]
28. Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid. Kaye A; Gordon SC; Deverapalli SC; Her MJ; Rosmarin D JAMA Dermatol; 2018 Oct; 154(10):1225-1226. PubMed ID: 30140849 [No Abstract] [Full Text] [Related]
30. Successful treatment of bullous pemphigoid with omalizumab. London VA; Kim GH; Fairley JA; Woodley DT Arch Dermatol; 2012 Nov; 148(11):1241-3. PubMed ID: 23165827 [No Abstract] [Full Text] [Related]
31. PD-L1 positive macrophages were increased in a case of pembrolizumab-induced bullous pemphigoid. Nakai K; Sato Y; Kubo S; Tsuruta D J Dermatol; 2021 Mar; 48(3):e146-e148. PubMed ID: 33439513 [No Abstract] [Full Text] [Related]
32. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report. Vico-Alonso C; Calleja-Algarra A; Aragón-Miguel R; Sánchez-Velázquez A; Velasco-Tamariz V; Ortiz-Romero PL; Monsálvez-Honrubia V Dermatol Ther; 2019 Mar; 32(2):e12829. PubMed ID: 30659716 [TBL] [Abstract][Full Text] [Related]